Post by Helsinn Group

Two days ago, we had the pleasure of hosting a Global Brand Meeting at our Lugano headquarters focused on our product for the treatment of Mycosis Fungoides-Cutaneous T-Cell Lymphoma (MF-CTCL). Together with our partners, Recordati, Arrotex Pharmaceuticals, Rafa, and our own US team from Helsinn Therapeutics (U.S.), Inc., we exchanged best practices, reviewed ongoing medical and marketing activities, and aligned on future plans. By combining our expertise and resources, we aim to raise awareness of MF-CTCL, support earlier diagnosis, and ultimately help improve outcomes and quality of life for patients. Partnerships are a key strength of our approach, enabling us to keep improving our solutions and better address patients’ needs. Together, we continue to make progress in the fight against rare diseases, helping ensure that no patient is left behind. #Helsinn #GlobalBrandMeeting #Partnerships